Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers

Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a...

Full description

Bibliographic Details
Main Authors: Michael Ulm, Arvind V Ramesh, Keely M McNamara, Suriyan Ponnusamy, Hironobu Sasano, Ramesh Narayanan
Format: Article
Language:English
Published: Bioscientifica 2019-02-01
Series:Endocrine Connections
Subjects:
Online Access:https://ec.bioscientifica.com/view/journals/ec/8/2/EC-18-0425.xml
id doaj-7d0aac4c1e994aafb0e02f6435b03e06
record_format Article
spelling doaj-7d0aac4c1e994aafb0e02f6435b03e062020-11-25T02:14:53ZengBioscientificaEndocrine Connections2049-36142049-36142019-02-0182R10R26https://doi.org/10.1530/EC-18-0425Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancersMichael Ulm0Arvind V Ramesh1Keely M McNamara2Suriyan Ponnusamy3Hironobu Sasano4Ramesh Narayanan5University of Tennessee Health Science Center, Memphis, Tennessee, USA; West Cancer Center, Memphis, Tennessee, USAWhite Station High School, Memphis, Tennessee, USATohoku University, Miyagi, JapanUniversity of Tennessee Health Science Center, Memphis, Tennessee, USATohoku University, Miyagi, JapanUniversity of Tennessee Health Science Center, Memphis, Tennessee, USA; West Cancer Center, Memphis, Tennessee, USAHormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.https://ec.bioscientifica.com/view/journals/ec/8/2/EC-18-0425.xmlprostate cancerbreast cancerovarian cancertherapeuticsdrug development
collection DOAJ
language English
format Article
sources DOAJ
author Michael Ulm
Arvind V Ramesh
Keely M McNamara
Suriyan Ponnusamy
Hironobu Sasano
Ramesh Narayanan
spellingShingle Michael Ulm
Arvind V Ramesh
Keely M McNamara
Suriyan Ponnusamy
Hironobu Sasano
Ramesh Narayanan
Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
Endocrine Connections
prostate cancer
breast cancer
ovarian cancer
therapeutics
drug development
author_facet Michael Ulm
Arvind V Ramesh
Keely M McNamara
Suriyan Ponnusamy
Hironobu Sasano
Ramesh Narayanan
author_sort Michael Ulm
title Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
title_short Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
title_full Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
title_fullStr Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
title_full_unstemmed Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
title_sort therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
publisher Bioscientifica
series Endocrine Connections
issn 2049-3614
2049-3614
publishDate 2019-02-01
description Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.
topic prostate cancer
breast cancer
ovarian cancer
therapeutics
drug development
url https://ec.bioscientifica.com/view/journals/ec/8/2/EC-18-0425.xml
work_keys_str_mv AT michaelulm therapeuticadvancesinhormonedependentcancersfocusonprostatebreastandovariancancers
AT arvindvramesh therapeuticadvancesinhormonedependentcancersfocusonprostatebreastandovariancancers
AT keelymmcnamara therapeuticadvancesinhormonedependentcancersfocusonprostatebreastandovariancancers
AT suriyanponnusamy therapeuticadvancesinhormonedependentcancersfocusonprostatebreastandovariancancers
AT hironobusasano therapeuticadvancesinhormonedependentcancersfocusonprostatebreastandovariancancers
AT rameshnarayanan therapeuticadvancesinhormonedependentcancersfocusonprostatebreastandovariancancers
_version_ 1724899113104834560